Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
09:00:34 EDT Mon 29 Apr 2024
Enter Symbol
or Name
USA
CA



Q:ACET - ADICET BIO INC - http://www.aceto.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ACET - Q0.41.70·1.910.21.681.3131    7.50  1.1008:42:30Apr 2215 min RT 2¢

Recent Trades - Last 10 of 31
Time ETExPriceChangeVolume
08:42:30Q1.70010.02013
08:41:21Q1.70090.02093
08:40:12Q1.700.023
08:39:32Q1.70150.02153
08:37:53Q1.70010.02013
08:36:44Q1.70010.02013
08:35:35Q1.700.023
08:34:27Q1.70010.02013
08:33:16Q1.70010.02013
08:27:31Q1.70010.02013

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-22 16:30U:ACETNews ReleaseAdicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
2024-04-08 07:00U:ACETNews ReleaseAdicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference
2024-03-28 17:19U:ACETNews ReleaseAdicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
2024-03-19 16:10U:ACETNews ReleaseAdicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
2024-03-11 07:00U:ACETNews ReleaseAdicet Bio to Participate in a Fireside Chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
2024-02-29 19:46U:ACETNews ReleaseAdicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
2024-01-31 16:39U:ACETNews ReleaseAdicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
2024-01-25 16:01U:ACETNews ReleaseAdicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering and Exercise in Full of the Underwriters ¢ € ™ Option to Purchase Additional Shares
2024-01-22 23:43U:ACETNews ReleaseAdicet Bio, Inc. Announces Pricing of Public Offering
2024-01-22 16:28U:ACETNews ReleaseAdicet Bio, Inc. Announces Proposed Public Offering
2024-01-04 07:00U:ACETNews ReleaseAdicet Provides Corporate Update and Highlights Strategic Priorities for 2024
2024-01-03 16:01U:ACETNews ReleaseAdicet Bio to Host Conference Call to Provide Updates on its Clinical Pipeline and Corporate Outlook
2023-12-29 16:50U:ACETNews ReleaseAdicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
2023-12-10 12:00U:ACETNews ReleaseAdicet Bio Highlights ADI-001 Expansion, Persistence and Pharmacodynamic Profile from Ongoing Phase 1 Study at the 65th American Society of Hematology (ASH) Annual Meeting
2023-11-08 16:10U:ACETNews ReleaseAdicet Reports Third Quarter 2023 Financial Results and Provides Business Updates
2023-11-07 07:00U:ACETNews ReleaseAdicet Bio to Present at the 2023 Jefferies London Healthcare Conference
2023-11-02 09:00U:ACETNews ReleaseAdicet Bio Announces Poster Presentation Highlighting ADI-001 Data at the 65th American Society of Hematology (ASH) Annual Meeting
2023-10-31 18:25U:ACETNews ReleaseAdicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
2023-10-04 12:00U:ACETNews ReleaseAdicet Bio Announces Poster Presentation at the Upcoming 2023 Molecular Targets and Cancer Therapeutics Conference
2023-09-29 17:24U:ACETNews ReleaseAdicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)